Market Highlights
Asia Pacific interventional cardiology market is expected to grow at a CAGR of 7.9% during forecasted period 2017-2023.
Interventional cardiology is the branch of cardiology which was develop by Andreas Gruentzig. This technique involves the use of catheter and stents for the treatment of heart diseases. According to World Health Organization (WHO), Asia Pacific has the largest number of population suffering from cardiovascular diseases owing to huge diabetic and obese population. The major driving factors for the growth of the market are increasing prevalence diabetes, heart attack and obesity. Changing lifestyle, lack of exercise and rapid development in medical devices had also contributed in growth of the market. Whereas on other hand, high cost of manufacturing devices and strict regulatory rules for development of catheter and stents had hamper the growth of the market.
Competitive Analysis
The major key player for the Asia Pacific interventional cardiology market are Abbott Laboratories Inc. (U.S.), B. Braun Melsungen AG (Germany), C.R. Bard, Inc. (U.S.), Abiomed Inc. (U.S), Edwards Lifesciences (U.S.), Biosensors International Group, Ltd. ( Singapore), Boston Scientific Corporation (U.S.), Medtronic PLC (Ireland), Angiodynamics, Inc. ( U.S), Terumo Medical Corporation (Japan), Johnson & Johnson Services, Inc. (U.S.)., Lombard Medical Technologies, Plc. (U.K), Clearstream Technologies Group Plc. (Ireland).
Fill Out Details To Receive FREE Sample Here@ https://www.marketresearchfuture.com/sample_request/1188

Intended Audience
• Research and Development (R&D) Companies
• Catheter manufacturing company
• Government and Independent Research Laboratories
• Government and Independent Regulatory Authorities
• Medical Research Laboratories
• Academic Medical Institutes and Universities

Segmentation:
Asia Pacific interventional cardiology market is segmented on the basis of type, into catheters, stents, balloons, vascular closure devices, laser procedures, atherectomy and other. Stents are sub segmented into metal stents, drug eluting stents and bioresorbable stents. Balloons are further segmented into cutting balloons, drug eluting balloons and other. On the basis of end users the market is segmented into catheterization laboratories, hospitals and clinics and others
Due to increasing prevalence of diseases like diabetes and cardiovascular diseases in the Asia Pacific region and increasing demand for the better treatment has attracted many of the major and medium sized company to introduce the better for the treatment. Many companies are focusing on development of the new drugs and method so as to withstand the competition and increase the market. Some major has adopted strategies of acquisitions and strategic alliances for the growth of the market.